MEDICREA Reports First Half 2017 Sales

LYON, France & NEW YORK--(BUSINESS WIRE)--The Medicrea Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, announced today sales for the first half of 2017.

2017 First Half Sales

€ millions

H1 2016

H1 2017

Variation

Sales

14.8

14.7

-1%

Movements in exchange rates had no significant impact on the evolution of sales over the period

Group sales remained steady over the first half of 2017 compared to the previous year despite solid performance during the month of June, notably in the U.S. where sales increased 10% over the prior year period. The global breakdown of the Group’s revenue demonstrates an ongoing growth trend in France, the Company’s domestic direct sales market, where sales increased by 8% compared to the first half of 2016. In Brazil, the Company’s historic leading export distribution market, the Company continued to face challenges related to local economic and regulatory factors leading to a 63% decrease in sales in the period compared to H1 2016. In April 2017, the Brazilian regulatory body, ANVISA, performed a long-awaited mandatory inspection of the Company’s recently-opened combined headquarters and manufacturing facilities in France. Following the successful ANVISA inspection, activity with Brazil is expected to resume in early 2018.

Revenue generated by Medicrea’s UNiD™ ASI systems technology for personalized spine continued to accelerate throughout the first half of 2017, particularly in the U.S. where a growth of 41% was seen compared to the first half of 2016. Since the Company FDA-cleared the first-ever personalized approach to spine surgery with patient-specific implants in November of 2014, the number of cases performed in the U.S. has now surpassed the total internationally and reached more than $15 million in cumulative sales at the end of the first half of 2017 for UNiD™ TEK and associated Medicrea implants, particularly the patient-specific UNiD Rod used in conjunction with the Company’s portfolio of PASS® spinal systems for degenerative and complex spinal indications.

As of the end of the first half of 2017, more than 1,500 UNiD™ ASI surgeries have been performed worldwide with a record number of UNiD™ TEK, patient-specific implants, manufactured and used in surgery during the month of June. The Company also performed the world’s first personalized minimally-invasive spine surgery in the U.S. by developing and launching patient-specific UNiD™ MIS Rod for minimally-invasive spine surgery.

Denys Sournac, President and CEO of Medicrea, stated, “The significant FDA clearances obtained in the first half of 2017 evidence the Company’s focus of placing UNiD™ ASI technology for Adaptive Spine Intelligence into the hands of surgeons. We are creating easy-to-use compatible implant hardware and IT software systems that surgeons know and trust. The addition of PASS® TULIP will open new doors for Medicrea to gain market share for our patient-specific UNiD™ Rod, by lowering the barrier to entry for the large number of surgeons trained on top-loading instrumentation.”

Recently, the Company announced FDA clearance of the UNiD™ HUB, a data-driven digital portal with surgical strategy and predictive modeling functionality, as well as the FDA clearance for and first U.S. surgery with the PASS® TULIP top-loading fixation, presenting an elegant solution to surgeons trained on this system - the global standard for posterior fixation.

Next financial publication: Results for the 1st half of 2017: September 28, 2017, after market.

About Medicrea (www.Medicrea.com)

Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 100,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

For further information, please visit: Medicrea.com.

Connect with Medicrea:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED